Avid Bioservices Inc (CDMO)

[keep_trying]

Oops, the faction on Item T was for that Phase 2 study where the dose switching left PPHM retail shareholders "at the altar" after the run up to over $5 1/2 pps, pre split. The Phase 3 trial halt was on its own path. There were at least three unusual trial results related events that left expectations for PPHM successful commercialization with a set back, by my recollection:
1. the unusual control group performance that showed the placebo group outperforming previous trial control groups by a large margin.
2. the Phase 2 trial dose mislabeling that resulted in some control group patients being administered Bavi. Intent behind that CSM fiasco remains a mystery.
3. the Phase 3 trial halt, which was announced on Friday's investor call to have provided stat sig results from a patient subgroup.

These don't even address the China TNT fiasco where Avid was supposed to be given orders for production that never happened.

Best wishes and IMO.
KT